Teva, AstraZeneca End Byetta Patent Dispute

Teva Pharmaceuticals USA Inc. and AstraZeneca Pharmaceuticals LP ended their patent dispute over Teva’s bid to make a generic version of Byetta, Teva said June 23 (AstraZeneca Pharmaceuticals LP et al v. Teva Pharmaceuticals USA, Inc.proposed consent judgment filed).

Under the parties’ settlement, Teva will get a license allowing it to market its generic version of the injectable treatment for type 2 diabetes in the U.S. on Oct. 15, 2017, or earlier under certain circumstances.

All other terms of the agreement are confidential, the parties said.

Teva’s Generic Injectable Plans.

AstraZeneca’s Byetta (exenatide injection) is an injectable product ...